Boston Scientific Corp. will be entering a $15bn market opportunity over the next four years, according to CEO and chairman Mike Mahoney, who also revealed a positive outlook for the company's upcoming Q4 and fiscal 2017 earnings results.
JPM2018: $15bn Market Opp Awaits Boston Scientific, Forecasts Mahoney
Boston Scientific CEO and chairman Mike Mahoney provided a positive preliminary Q4 earnings outlook during his presentation at the JP Morgan HealthCare Conference on Jan. 9, and outlined plans for the medical device giant's growth for 2018 and beyond, including a $15bn market opportunity between 2018 and 2021.
More from Business
• By
Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.
• By
Abbott presented late-breaking data at the 2025 American College of Cardiology conference demonstrating that TriClip transcatheter edge-to-edge repair offers prolonged patient benefits compared to medical treatment alone after two years, which were not evident at one year.
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.